Target Progenitor Cells of Multiple Myeloma

From Cancer Research & Technology

Multiple myeloma is a cancer of the bone marrow. Proteasome inhibitor drugs such as Velcade have proven effective at initially treating the disease, but even in patients who appeared to be in complete remission is always seemed to come back.

Turns out, that’s because it’s only mature myeloma cells that are sensitive to proteasome inhibition; the progenitor cells are unaffected by the drug, leaving them free to proliferate and mature, causing a resurgence of the disease. Which means that proteasome inhibitors will never, on their own, be able to fully cure multiple myeloma.

Knowing the cause of the treatment failure, new drugs, or existing drugs able to target the progenitor cells, can now be sought that will be able to target the progenitor cells.

Press release:

Image: Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps understand hematopathology. Wikimedia Commons
#cancerresearch #myeloma #multiplemyeloma


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s